Cingulate Inc.Cingulate Inc.Cingulate Inc.

Cingulate Inc.

No trades
See on Supercharts
Market capitalization
‪2.35 M‬USD
−23.9053USD
‪−23.53 M‬USD
‪5.48 M‬
Beta (1Y)
−6.55

About Cingulate Inc.

CEO
Shane J. Schaffer
Headquarters
Kansas City
Employees (FY)
13
Founded
2013
FIGI
BBG013YMVH68
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.